All In Biotech

NDA 209229 · Biocorrx Pharms

Lucemyra

Lofexidine Hydrochloride · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Sep 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 16, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

40

6 Phase 3, 1 recruiting

FAERS reports

163

46 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 22, 2026.

Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Lofexidine tablets are a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. ( 1 )

Mechanism: Lofexidine tablets are a central alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 16, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • LUCEMYRA · LOFEXIDINE HYDROCHLORIDE EQ 0.18MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lofexidine" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness24
  • hypotension17
  • somnolence15
  • dyspnoea14
  • diarrhoea13
  • dry mouth11
  • fatigue11
  • insomnia11
  • malaise10
  • vomiting10
  • withdrawal syndrome10
  • drug withdrawal syndrome9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20061
20111
20141
20155
20166
201819
201968
202023
20218
20229
20234
20248
20255
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lucemyra (Lofexidine HCl)

2024 spending

$1.9M

Beneficiaries

446

597 claims

Per beneficiary

$4,359

$23.96 per unit

View as table
YearSpending
2020$0
2021$1,214,485
2022$2,479,909
2023$3,148,076
2024$1,944,300

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 76 on PubMed

Sponsor: Biocorrx Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.